Duraol

# Duraol ## Overview - **Classification**: Selective Alpha-1 Adrenergic Blocker - **Mechanism**: Blocks alpha-1 receptors, causing vasodilation and smooth muscle relaxation. Reduces peripheral vascular resistance. ## Primary Indications 1. **Benign Prostatic Hyperplasia (BPH)** - Symptomatic relief of urinary outflow obstruction. 2. **Hypertension** - Management of essential hypertension. 3. **Pheochromocytoma (Off-label)** - Adjunctive management of hypertensive crises. ## Adult Dosing ### Standard Dosing **Benign Prostatic Hyperplasia (BPH)** - **Dose**: **2 mg** - **Frequency**: Once daily (HS - at bedtime) - **Route**: Oral - **Duration**: Long-term for symptom control **Hypertension** - **Dose**: **1 mg** - **Frequency**: Once daily - **Route**: Oral - **Maximum**: Up to **8 mg** daily based on response ### Dose Adjustments - **Renal Impairment**: CrCl <30 mL/min: Start with **1 mg** once daily. Titrate cautiously. - **Hepatic Impairment**: Mild-moderate: Start with **1 mg** once daily. Monitor closely. Severe: Avoid use. - **Elderly Patients**: Start with **1 mg** once daily due to increased sensitivity to hypotensive effects. Titrate slowly. ## Pediatric Dosing ### Neonates (0-28 days) - **Use not established**: Duraol is generally not recommended in neonates. - **Special Notes**: Safety and efficacy not determined. Avoid unless benefits clearly outweigh risks in life-threatening situations. ### Infants (1-12 months) - **Use not established**: Duraol is generally not recommended in infants. - **Special Notes**: Data are insufficient. Consider alternative therapies. ### Children (1-12 years) - **Hypertension (Limited Data)**: **0.02 mg/kg** - **Frequency**: Once daily - **Maximum**: **1 mg** initial dose; up to **0.2 mg/kg** or **8 mg** daily. - **Special Notes**: Use only in specific cases, e.g., pheochromocytoma, under specialist guidance. ### Adolescents (13-18 years) - **Dose**: Refer to adult dosing guidelines. Start with **1 mg** once daily. - **Maximum**: **8 mg** daily. - **Special Notes**: Closely monitor for orthostatic hypotension, especially with initial dose. ## Safety Information ### Contraindications - **Absolute**: Hypersensitivity to Duraol or other alpha-blockers. - **Absolute**: History of orthostatic hypotension/syncope. - **Relative**: Concurrent use of phosphodiesterase-5 (PDE5) inhibitors. ### Common Adverse Effects - **Very Common (>10%)**: Dizziness, Headache, Drowsiness, Orthostatic Hypotension. - **Common (1-10%)**: Nausea, Palpitations, Nasal congestion, Edema. - **Serious but Rare**: Priapism, Severe hypotensive episodes leading to syncope, Intraoperative Floppy Iris Syndrome (IFIS). ### Key Drug Interactions - **PDE5 Inhibitors (e.g., sildenafil)**: Potentiates hypotensive effect. Administer 4-6 hours apart. - **Other Antihypertensives**: Additive hypotensive effects. Monitor BP closely. - **Beta-blockers**: Increased risk of first-dose syncope. Initiate Duraol at bedtime. ## Monitoring & Follow-up - **Before Treatment**: Baseline blood pressure (sitting & standing), urinalysis (for BPH). - **During Treatment**: Blood pressure (sitting & standing) regularly, especially after dose changes. Assess BPH symptom score. - **Clinical Signs**: Monitor for dizziness, lightheadedness, syncope (especially after first dose or dose increase). ## Clinical Pearls - 💡 **First-Dose Syncope**: Administer the first dose at bedtime to minimize the risk of orthostatic hypotension and syncope. - 💡 **Titration**: Doses should be titrated slowly to minimize adverse effects, especially hypotension. - 💡 **IFIS Risk**: Inform ophthalmologists if a patient is on Duraol before cataract surgery. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.